Vinorelbine 10mg Injection Neoben

Trade Name: Neoben

Manufacturer: Neon Laboratories Ltd

Presentation: Injection

Strength: 10mg

What is the best way to administer Vinorelbine 10 mg Injection?

Vinorelbine 10 mg Injection is available as a liquid solution that is administered intravenously (into a vein) by a doctor or nurse in a medical setting. It is typically administered once a week. The length of treatment is determined by how well your body responds to vinorelbine treatment.

What is the frequency of vinorelbine administration?

Oral vinorelbine should be taken at a dose of 60 mg/m(2) weekly for the first three weeks (cycle 1) and then 80 mg/m(2) weekly after that. If severe neutropenia develops during the first cycle, therapy is continued with 60 mg/m weekly dosages (2).

What are the risks of taking vinorelbine?

It is possible to experience nausea, vomiting, lethargy, constipation, diarrhea, disorientation, muscular aches, joint pain, or discomfort at the injection site. If any of these adverse effects persist or worsen, contact your doctor or pharmacist right away. It’s possible that you’ll lose some hair temporarily. Normal hair growth should continue after the operation.

What is the Vinorelbine 10 mg Injection antidote?

  • There is no specific antidote that has been discovered.
  • In the event of infection-related problems, broad-spectrum antibiotic therapy may be required.
  • There is no recognized antidote for vinorelbine overuse. Vinorelbine belongs to the Vinca alkaloid family of cytostatic drugs. For more details Click Here.

Is it true that vinorelbine causes constipation?

This medicine can produce severe constipation, which can lead to death from bowel blockage, intestinal rips, or gut tissue death. If you have constipation, rectal pain, or rectum bleeding, call your doctor straight away. If the medicine spills from the vein, it may cause tissue injury.

When did vinorelbine become available?

Vinorelbine 10 mg Injection was developed in the 1980s by pharmacist Pierre Potier and his colleagues at the CNRS in France and was licensed to the Pierre Fabre Group’s oncology section. In 1989, the medicine was licensed in France for the treatment of non-small cell lung cancer under the trade name Navelbine.

Is vinorelbine able to pass through the blood-brain barrier?

The majority of commonly used cytotoxic chemotherapy agents (primarily taxanes and vinorelbine, but also pemetrexed and gemcitabine) do not readily cross the intact blood-brain barrier or are actively pumped out; responses that are occasionally reported may be insignificant and will not treat micrometastatic disease.

If you are looking for another product or brand click here.